Vancouver, British Columbia–(Newsfile Corp. – April 5, 2024) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company“), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants (the “Warrants“) originally issued as part of a private placement closed on November 16, 2022. The expiry date will be extended by 12 months and the exercise price will be repriced at $1.75 per Class A Common share, as follows:
|
Number of Warrants: |
Original Expiry Date of Warrants: |
New Expiry Date of Warrants: |
Original Exercise Price of Warrants: |
New Exercise Price of Warrants: |
|
1,497,780 |
November 16, 2024 |
November 16, 2025 |
$2.50 |
$1.75 |
All other terms of the Warrants will remain unchanged. In accordance with the requirements of the CSE, the terms of any warrants issued as compensation warrants or as finder…
